IBRX
Another lawsuit, because apparently one wasn’t enough
ImmunityBio (NASDAQ: IBRX) is back in the legal hot seat. A securities class action was filed against the company after the FDA sent a warning letter flagging allegedly misleading efficacy claims tied to Anktiva, its lead biologic product.
For investors, this is the annoying kind of news that can snowball fast. The lawsuit covers people who bought ImmunityBio shares between January 19, 2026 and March 24, 2026, which tells you the market thinks the alleged misstatements matter more than just a bad week of headlines.
Why the market cares
When the FDA starts waving a red flag, it’s not just a PR problem — it can turn into a trust problem. And once lawyers smell smoke, they usually show up with a fire extinguisher invoice.
What matters here:
- The FDA warning letter centers on allegedly misleading efficacy claims
- The lawsuit could add settlement costs, legal distractions, and more headline risk
- Shares reportedly plunged 21%, with about $2 billion in market value evaporating in the fallout
Big picture
This is the classic biotech one-two punch: regulatory scrutiny on one side, shareholder lawsuits on the other. If the company can’t clean up the messaging — and fast — investors may keep treating IBRX like a stock with a leaky roof rather than a growth story.